<DOC>
	<DOCNO>NCT01138163</DOCNO>
	<brief_summary>The primary purpose research study see whether add bavituximab ( investigational drug ) standard chemotherapy drug docetaxel , improve result treatment non-small-cell lung cancer .</brief_summary>
	<brief_title>Study Bavituximab Plus Docetaxel Patients With Locally Advanced Metastatic Non-Squamous Non Small-Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adults age 18 year age life expectancy least 3 month . Histologically cytologically confirm stage IIIB stage IV non squamous nonsmallcell lung cancer ( NSCLC ) progress 1 chemotherapy regimen . Measurable disease Response Evaluation Criteria In Solid Tumors ( RECIST , Version 1.1 ) crosssectional image least 2 cm long diameter . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 . Adequate hematologic , renal , hepatic function . PT/INR ≤ 1.5 × ULN ; aPTT time ≤ 1.5 × ULN . New York Heart Association classification I II Squamous , small cell , mixed histology . Known history bleed diathesis coagulopathy . Cavitary tumor tumor invade abut large blood vessel . Bleeding : Clinically significant bleeding gross hematuria , GI bleed hemoptysis within 12 month Screening . Venous thromboembolic event within 6 month screen . Ongoing therapy oral parenteral anticoagulant . Concurrent estrogens , antiestrogens progesterone compound . Radiotherapy within 2 week major surgery within 4 week precede Study Day 1 . Symptomatic clinically active brain metastasis . Symptomatic coronary artery disease , cerebrovascular accident , transient ischemic attack , myocardial infarction unstable angina pectoris within 6 month screen . Grade 2 high peripheral neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>second-line</keyword>
	<keyword>lung cancer</keyword>
	<keyword>non small cell lung cancer</keyword>
	<keyword>bavituximab</keyword>
	<keyword>monoclonal antibody</keyword>
</DOC>